Salubris Biotherapeutics’ Post

Can the SteriPlas: Kill all forms of bacteria? YES ✔   Kill bacteria protected within #biofilm? YES ✔   Operate safely with no side effects? YES ✔   Treat infected #wounds in as quick as 2 minutes? YES ✔   Ready to learn more? Visit our website: https://lnkd.in/eB2G8xgm   Our 80 peer-reviewed clinical trials and publications illustrate why our SteriPlas remains the leader for #ColdPlasma with anti-biofilm efficacy.   #medicaldistributor #MEDICA2023 #ABHI #Plasma #investorswanted #investor  

📰 #SharingThursday "There are ~7,000 rare diseases that together affect 300 million people. For the vast majority of these patients there are no approved treatments, representing a huge unmet medical need". A new article from our president James Levine and our colleague Clea Stemitsiotis published in Nature Reviews and completely free for one week! "De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors" 🤝 Read it now 👇 https://lnkd.in/gze9Jd4g #raredisease #medicalresearch #sciences #derisking #biotech

Today, on #Juneteenth, we don't just celebrate liberation – we ignite it. At Molekule Consulting LLC, we channel the unyielding spirit of those who fought for freedom into our relentless pursuit of groundbreaking biopharma solutions. Just as the echoes of Juneteenth reverberate through history, our impact echoes through the lives transformed by the medicines we help bring to the world. We shatter barriers, defy limitations, and rewrite the rules of what's possible in healthcare. But our work is far from finished. The struggle for health equity is a marathon, not a sprint. We stand shoulder-to-shoulder with those who continue to fight for a world where every life is valued, every voice is heard, and every person has the opportunity to thrive. On this Juneteenth, we don't just honor the past – we forge the future. Join us as we revolutionize healthcare, empower communities, and create a legacy of progress that burns as brightly as the Juneteenth sun. #DiversityInBiopharma #Innovation #Pharma #HealthEquity

Today, on #Juneteenth, we don't just celebrate liberation – we ignite it. At Molekule Consulting LLC, we channel the unyielding spirit of those who fought for freedom into our relentless pursuit of groundbreaking biopharma solutions. Just as the echoes of Juneteenth reverberate through history, our impact echoes through the lives transformed by the medicines we help bring to the world. We shatter barriers, defy limitations, and rewrite the rules of what's possible in healthcare. But our work is far from finished. The struggle for health equity is a marathon, not a sprint. We stand shoulder-to-shoulder with those who continue to fight for a world where every life is valued, every voice is heard, and every person has the opportunity to thrive. On this Juneteenth, we don't just honor the past – we forge the future. Join us as we revolutionize healthcare, empower communities, and create a legacy of progress that burns as brightly as the Juneteenth sun. #DiversityInBiopharma #Innovation #Pharma #HealthEquity

🔍 Curious About What Happens During Drug #Detox? The journey to recovery begins with detoxification, but what exactly goes on during this vital process? Our latest blog post sheds light on the intricate stages of #drugdetox: 🌟 Assessment 🌟 Detox 🌟 #Withdrawal Stabilization Ready to embark on your #RecoveryJourney? Read the full article now: https://bit.ly/3MJYv7s

What is #PTRS, how is it used, & what’s at stake? 🤔 PTRS is an estimate of a drug development program’s probability of success based on a technical (PTS) and regulatory (PRS) analysis. How is it used?👇 PTRS is integral to the #drugdevelopment process, used by companies to make informed decisions about which drug candidates to advance, to allocate resources effectively, and to navigate the increasingly complex regulatory requirements. What’s at stake?👇 With drug development costs ranging from “$314 million to $2.8 billion” according to JAMA, the importance of PTRS accuracy is critical for drug development forecasting. Looking for more insights about PTRS? Subscribe to our newsletter: https://lnkd.in/gc5MBZBy

#Biosimilars have been on the market for years now. Have they been a boom or a bust for plan sponsors? This week on the blog, Mark Matusik is breaking down realities of pursuing savings with biosimilars space and how plan sponsors can adapt their strategy. As a bonus, tune in as Mark, Megan Dorrell, PharmD, BCACP and Amy Ball break down everything you need to know about this category in our July 10th webinar. Links in the comments! #pharmacybenefitsconsulting

On #BiotechHangout today Daphne Zohar, Brad Loncar, John Maraganore, Josh Schimmer, Bruce Booth & Yaron Werber, M.D., MBA cover $ABBV / $IMGN $10B acquisition, FDA’s CAR-T safety concerns, data setbacks & wins ($ROIV, $ARGX, $XENE, & $IVMT), $REGN & $SNY seek to expand Dupixent approval to COPD, $SWTX approval, plus JAMA Internal Medicine paper calls to eliminate orphan drug exemptions, $SLRN & $BIVI point to CRO errors in trial failures, X Prize $101M prize in aging + financings/biotech sentiment Listen here: https://lnkd.in/ejhkm9BY

I am delighted to announce the release of Microba Life Sciences (ASX: MAP) Q4 FY24 Activities Report and 4C Report & Investor Presentation to the ASX today. This quarter, Microba achieved the following significant milestones: Revenue & Cash Receipts Growth: Microba is pleased to announce significant revenue growth this quarter, with a 20% increase QoQ and a 113% rise YoY, and cash receipts up 15.7% QoQ and 275% YoY. This traction in market highlights the growing market demand for our industry-leading microbiome tests. Nationwide roll out of MetaPanel: We're excited to announce that MetaPanel, our groundbreaking gastrointestinal pathogen test recently launched with Sonic Healthcare, is seeing growing referrals and sales across Australia, with successful educational events and strong KOL engagement driving early adoption and setting the stage for growth in FY25. First 6 months of Invivo in the UK: Continued commercial progress continues following the acquisition of UK-based microbiome leader Invivo Healthcare, our incredible team at Invivo is well positioned for continued growth in FY25. Therapeutic Program Progression: During the quarter we advanced all 3 of our therapeutic programs, most importantly was the successful completion of our Autoimmune disease discovery program with US partner Ginkgo Bioworks, Inc.. Read the full details on these exciting advancements in our Quarterly Report and Investor Presentation via the links below. Quarterly Activities Report - https://loom.ly/oGfgiiY Investor Presentation & Webinar - https://loom.ly/6CGMBQE #Microbiome #LifeSciences #Healthcare #BioTech #ASX